Scholarlink

<p>In metabolic dysfunction-associated steatotic liver disease (MASLD), lipid accumulation and inflammatory stimulation lead to the release of damage-associated molecular patterns, thereby inducing the activation of the cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) signaling pathway. The cGAS-STING signaling pathway in the liver is primarily activated in Kupffer cells/macrophages, hepatic stellate cells, hepatocytes and liver sinusoidal endothelial cells. Emerging evidence also reveals that the cGAS-STING signaling pathway contributes to liver cell fate changes in MASLD. Herein, this review summarizes the role of the cGAS-STING signaling pathway in liver cells and its effect on cell fate in the context of MASLD and liver fibrosis. Therapeutic agents targeting the cGAS-STING signaling pathway may shed light on the clinical treatment of MASLD and liver fibrosis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

cGAS-STING signaling pathway in MASLD and liver fibrosis

  • 期刊论文

  • 发表日期：

    2026年1月15日

查看全文
  • Yang Xiao,
  • Yufang Ma,
  • Can Gan,
  • Zhiyin Huang,
  • Jinhang Gao

摘要

In metabolic dysfunction-associated steatotic liver disease (MASLD), lipid accumulation and inflammatory stimulation lead to the release of damage-associated molecular patterns, thereby inducing the activation of the cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) signaling pathway. The cGAS-STING signaling pathway in the liver is primarily activated in Kupffer cells/macrophages, hepatic stellate cells, hepatocytes and liver sinusoidal endothelial cells. Emerging evidence also reveals that the cGAS-STING signaling pathway contributes to liver cell fate changes in MASLD. Herein, this review summarizes the role of the cGAS-STING signaling pathway in liver cells and its effect on cell fate in the context of MASLD and liver fibrosis. Therapeutic agents targeting the cGAS-STING signaling pathway may shed light on the clinical treatment of MASLD and liver fibrosis.